Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03655834 | Dose Individualization of Pemetrexed - IMPROVE-III(IMPROVE-III) | completed | Phase 4 | 10 | Radboud University Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03607149 | Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies(PKAPIR) | completed | Phase 4 | 11 | Centre Georges Francois LeclercOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02514174 | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | completed | Phase 4 | 25 | Boehringer IngelheimINDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03550482 | Oncoxin® and Quality of Life in Cancer Patients | completed | Phase 4 | 133 | Catalysis SLINDUSTRY | 2 | Jun 5, 2019 | clinicaltrials |
| NCT03092986 | Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 4 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT02151149 | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly(ABOUND 70+) | completed | Phase 4 | 143 | CelgeneINDUSTRY | 1 | Sep 24, 2018 | clinicaltrials |
| NCT03384511 | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | completed | Phase 4 | 38 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT02316327 | Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab | completed | Phase 4 | 19 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01066884 | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT02000531 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | completed | Phase 4 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01196078 | A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02497118 | Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC | completed | Phase 4 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01287754 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations | completed | Phase 4 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT01230710 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression | completed | Phase 4 | 51 | Hoffmann-La RocheINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT01465243 | Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose | completed | Phase 4 | 32 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 17, 2014 | clinicaltrials |
| NCT00883675 | Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer | completed | Phase 4 | 133 | Michael MannNETWORK | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00762346 | Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis | completed | Phase 4 | 156 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00765687 | Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates(BLEST) | completed | Phase 4 | 432 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT01020786 | A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients | completed | Phase 4 | 109 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 27, 2013 | clinicaltrials |
| NCT00829322 | Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 | completed | Phase 4 | 208 | University of OxfordOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00608868 | SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients(SELINE) | completed | Phase 4 | 156 | AstraZenecaINDUSTRY | 1 | Sep 28, 2012 | clinicaltrials |
| NCT01442909 | Pemetrexed Followed by Docetaxel or in Reverse Sequence | completed | Phase 4 | 44 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 29, 2011 | clinicaltrials |
| NCT00686322 | Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) | completed | Phase 4 | 6 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00380718 | Chemotherapy for Patients With Non-Small Cell Lung Cancer | completed | Phase 4 | 33 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 16, 2010 | clinicaltrials |
| NCT01000740 | A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa | completed | Phase 4 | 59 | AstraZenecaINDUSTRY | 1 | May 21, 2010 | clinicaltrials |
| NCT00099541 | Non-small Cell Lung Cancer Registry | completed | Phase 4 | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00115206 | Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy | completed | Phase 4 | — | AmgenINDUSTRY | 0 | Apr 6, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 7, 2026source: clinicaltrials